Mode of Action VOYDEYA® (danicopan) is a selective inhibitor of Factor D: added to ULTOMIRIS® (ravulizumab) or SOLIRIS® (eculizumab), VOYDEAYA® (danicopan) provides dual inhibition of complement in patients with Paroxysmal nocturnal haemoglobinuria (PNH).1-2
advance I am a healthcare professional registered in the EU I am not a
healthcare professional
PNH is a rare, chronic, life-threatening disease affecting the complement cascade – a critical part of the normal innate immune response.4 Uncontrolled terminal complement activation impairs the normal functioning of blood cells and leads to life-threatening consequences such as intravascular haemolysis (IVH), thromboembolic event, renal impairment and pulmonary hypertension.3,5

In IVH, red blood cells (RBCs) are destroyed within the bloodstream, releasing haemoglobin into plasma and causing life-threatening consequences such as thrombosis and organ damage.6,7 Elevated lactate dehydrogenase (LDH) level (≥1.5 x ULN) is a key biomarker for IVH.8
Inhibition of C5-mediated terminal complement controls IVH of PNH RBCs.9,10 Surviving PNH RBCs are susceptible to deposition of C3b fragments that may lead to the premature destruction of RBCs outside the bloodstream – often in the liver and spleen – a process called EVH.7,11
  • Inhibition of C5-mediated terminal complement controls IVH of PNH RBCs.7,9-11

  • The PNH RBCs remaining in circulation are susceptible to C3 fragment deposition that may lead to EVH.7,12,13

  • In PNH, EVH does not indicate inadequate terminal complement inhibition7,11
In some patients EVH can lead to anaemia, as RBCs are destroyed faster than they are formed. However, for most patients with PNH receiving C5 inhibition therapy, anaemia (if present) is asymptomatic.9,10,13
Clinically significant EVH is associated with ongoing anaemia and fatigue, with consequences for patient quality of life and transfusion dependency.7,9

A subset of patients treated with a C5 inhibitor may experience cs-EVH.9,15 However, residual anaemia can be caused by several factors beyond EVH, including bone marrow dysfunction, low nutritional folate or iron overload, relative erythropoietin deficiency.9,14,16 In PNH, to confirm whether residual anaemia is due to EVH, other causes should be eliminated.17,18
ULTOMIRIS® is the critical backbone and standard of care for PNH treatment.21 By targeting uncontrolled terminal complement activity, it delivers immediate, complete and sustained C5 inhibition.16,18,22-24 ULTOMIRIS® also has a well established safety profile, backed by the largest body of evidence in complement inhibitor naïve patients with PNH to date.23,25

VOYDEYA® is an approved and selective inhibitor of Factor D of the alternative pathway, deposition of C3 fragments on PNH RBCs is prevented and consequent EVH can be decreased.1
*While clinically significant EVH is not defined by specific laboratory thresholds, the inclusion criteria in the Phase 3 ALPHA trial defined low haemoglobin as ≤9.5 g/dL and increased absolute reticulocyte count as ≥120×109/L.1,2

†Other causes of anaemia in patients receiving a C5 inhibitor include bone marrow dysfunction, low nutritional folate or iron levels, relative erythropoietin deficiency, breakthrough IVH, hypersplenism, iron overload and/or the presence of alloantibodies.11,18

‡Following ULTOMIRIS® treatment in both adult and paediatric complement inhibitor-naïve patients and eculizumab-experienced patients with PNH in Phase 3 studies, immediate, sustained and complete inhibition of serum free C5 (concentration of <0.5 μg/mL) was observed by the end of the first infusion and sustained throughout the entire 26-week treatment period in all patients.19,21-23
Even in the event of incomplete complement inhibition (due to infection, surgery, missed dose), dual inhibition may work synergistically to maintain disease control*.1,7,15,26
*Currently, the explanation offered for greater severity of breakthrough haemolysis with escape from C3 blockade vs escape from C5 blockade is theoretical.26
*VOYDEYA® may also be taken with SOLIRIS® (eculizumab).1
image
Do you know how to dose and administer VOYDEYA® ?
Dosing and Administration of Voydeya®

Adverse Event Reporting

Please report any adverse events via your national reporting system. Adverse events can also be reported to Alexion,
AstraZeneca Rare Disease by contacting: https://contactazmedical.astrazeneca.com/
C3b, complement component 3b; C5, complement component 5; cs, clinically significant; EVH, extravascular haemolysis; IVH, intravascular haemolysis; LDH, lactate dehydrogenase; LSM, least squares mean; PNH, paroxysmal nocturnal haemoglobinuria; RBC, red blood cell; SMPC, summary of product characteristics; ULN, upper limit of normal.
VOYDEYA® EU Summary of Product Characteristics available at: https://www.ema.europa.eu/en/documents/product-information/voydeya-epar-product-information_en.pdf.  Last accessed November 2025. Lee JW, et al. Addition of Danicopan to Ravulizumab or Eculizumab in Patients with Paroxysmal Nocturnal Haemoglobinuria and Clinically Significant Extravascular Haemolysis (ALPHA): a Double-Blind, Randomised, Phase 3 Trial. Lancet Haematol. 2023;10:e955–e965 Hill A, et al. Thrombosis in Paroxysmal Nocturnal Hemoglobinuria. Blood. 2013;121(25):4985–4996. Lee JW, et al. The Role of the Alternative Pathway in Paroxysmal Nocturnal Hemoglobinuria and Emerging Treatments. Expert Review of Clinical Pharmacology. 2022;15(7):851–861. Van Bijnen ST, et al. Mechanisms and Clinical Implications of Thrombosis in Paroxysmal Nocturnal Hemoglobinuria. Journal of Thrombosis Haemostasis. 2012;1(10):1–10. Lee JW, et al. Clinical Signs and Symptoms Associated with Increased Risk for Thrombosis in Patients with Paroxysmal Nocturnal Hemoglobinuria from a Korean Registry. International Journal of Hematology. 2013;6(97):749–757. Kulasekararaj AG, et al. The Importance of Terminal Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria. Therapeutic Advances in Hematology. 2022;13:20406207221091046. Jang J et al. Impact of Lactate Dehydrogenase and Hemoglobin Levels on Clinical Outcomes in Patients With Paroxysmal Nocturnal Hemoglobinuria: Results From the National Korean PNH Registry. Journal of Korean Medical Science 2024. Hill A, et al. Paroxysmal Nocturnal Haemoglobinuria. Nature Reviews Disease Primers. 2017;3:17028. Brodsky RA. Paroxysmal Nocturnal Hemoglobinuria. Blood. 2014;18(124):2804–2811. Shammo J, et al. Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Large, Multicenter, US Real-World Study. Journal of Blood Medicine. 2022;(13):425–437. Risitano AM, et al. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT. Frontiers in Immunology. 2019;10:1157. DeZern AE, et al. Predictors of Hemoglobin Response to Eculizumab Therapy in Paroxysmal Nocturnal Hemoglobinuria. European Journal of Haematology. 2013;90(1):16–24. Kulasekararaj AG, et al. One-year Outcomes From a Phase 3 Randomized Trial of Ravulizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria Who Received Prior Eculizumab. European Journal of Haematology. 2021;106(3):389–397. Kulasekararaj AG, et al. Long-term Safety and Efficacy of Ravulizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: 2-year Results from Two Pivotal Phase 3 Studies. European Journal of Haematology. 2022;3(109):205–214. Risitano AM, de Latour RP. How We('ll) Treat Paroxysmal Nocturnal Haemoglobinuria: Diving into the Future. British Journal of Haematology. 2022;196(2):288–303. Röth A, Dührsen U. Treatment of Paroxysmal Nocturnal Hemoglobinuria in the Era of Eculizumab. European Journal of Haematology. 2011;87(6):473–479. Kulasekararaj AG, et al. Monitoring of patients with paroxysmal nocturnal hemoglobinuria on a complement inhibitor. American Journal of Haematology 2021. ULTOMIRIS® EU Summary of Product Characteristics available at: https://www.ema.europa.eu/en/documents/product-information/ultomiris-epar-product-information_en.pdf. Last accessed November 2025. Kulasekararaj AG et al. Paroxysmal Nocturnal Hemoglobinuria: Where are we going. American Journal of Hematology. 2023;98:S33–S43. Chonat S, et al. Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Ravulizumab in Pediatric Paroxysmal Nocturnal Hemoglobinuria. Blood Advances. 2024;8(11):2813–2824. Kulasekararaj AG, et al. Ravulizumab (ALXN1210) vs Eculizumab in Adult Patients with PNH Naive to Complement Inhibitors: the 301 Study. Blood. 2019;6(133):540–549. Lee JW, et al. Ravulizumab (ALXN1210) vs Eculizumab in Adult Patients with PNH Naive to Complement Inhibitors: the 301 Study. Blood. 2019;6(133):530–539. Schrezenmeier H, et al. One-year Efficacy and Safety of Ravulizumab in Adults with Paroxysmal Nocturnal Hemoglobinuria Naive to Complement Inhibitor Therapy: Open-Label Extension of a Randomized Study. Therapeutic Advances in Hematology. 2020;11:2040620720966137. Kulasekararaj AG, et al. Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria. Annals of Hematology 2025. Notaro R, Luzzatto L. Breakthrough Hemolysis in PNH with Proximal or Terminal Complement Inhibition. New England Journal of Medicine. 2022;2(387):160–166.